EY unveils Dr. Patel & Dr. Smith as finalists for Entrepreneur Of The Year® 2025 Southeast Award

EY unveils Dr. Barry Patel & Dr. Wade Smith as finalists for Entrepreneur Of The Year® 2025 Southeast Award

Scott Chappell
Scott Chappell

Galt Pharmaceuticals Director of Medical Affairs

EY US unveils Dr. Barry Patel and Dr. Wade Smith of Galt Companies as an Entrepreneur Of The Year® 2025 Southeast Award finalist

ATLANTA, GA, UNITED STATES, April 28, 2025 /EINPresswire.com/ — Ernst & Young LLP (EY US) announced the finalists for the prestigious Entrepreneur Of The Year 2025 Southeast Award. The Southeast program celebrates entrepreneurs from Alabama, Georgia, North Carolina, South Carolina and Tennessee. Now in its 40th year, the Entrepreneur Of The Year program celebrates the bold leaders who disrupt markets through the world’s most ground-breaking companies, revolutionizing industries and making a profound impact on communities. The program honors bold entrepreneurs whose innovations shape the future and pave the way for a thriving economy and a hopeful tomorrow.

An independent panel of judges selected Dr. Barry Patel and Dr. Wade Smith among 36 finalists for their entrepreneurial spirit, purpose, growth and lasting impact in building long-term value.

About Galt Companies
Galt Companies is the parent organization of Galt Pharmaceuticals and Galt Phranchise Systems. Galt Pharmaceuticals focuses on acquiring, developing, and commercializing prescription medications with strong product-market fit—targeting areas of unmet clinical need. The company brings its medications to market through four distinct sales channels, including the industry’s first-ever pharmaceutical franchising model: Galt Phranchise Systems. This innovative approach empowers healthcare entrepreneurs to build localized, community-driven pharmaceutical businesses under the Galt brand.

Quote from Barry Patel, CEO of Galt Companies
“We’re incredibly honored to be named finalists for the EY Entrepreneur of the Year award,” said Barry Patel, CEO and co-founder of Galt Companies. “Wade and I built Galt alongside a team that has shown remarkable resilience and commitment through every challenge. This recognition is a reflection of their passion, perseverance, and belief in doing things differently to improve healthcare.”

Entrepreneur Of The Year honors business leaders for their ingenuity, courage and entrepreneurial spirit. The program celebrates original founders who bootstrapped their business from inception or who raised outside capital to grow their company; transformational CEOs who infused innovation into an existing organization to catapult its trajectory; and multigenerational family business leaders who reimagined a legacy business model to strengthen it for the future.

Regional award winners will be announced on June 25 during a special celebration in Atlanta, GA and will become lifetime members of an esteemed community of Entrepreneur Of The Year alumni from around the world. The winners will then be considered by the National judges for the Entrepreneur Of The Year National Awards, which will be presented in November at the annual Strategic Growth Forum®, one of the nation’s most prestigious gatherings of high-growth, market-leading companies.

Sponsors
Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Awards include presenting sponsors PNC Bank, Cresa, LLC, Marsh USA, and SAP. In the Southeast, sponsors also include VACO, LLC as the regional Platinum sponsor; ADP and King & Spalding as the regional Gold sponsors; and Babbit Bodner as the regional Silver sponsor.

About Entrepreneur Of The Year
Founded in 1986, Entrepreneur Of The Year has celebrated more than 11,000 ambitious visionaries who are leading successful, dynamic businesses in the US, and it has since expanded to nearly 60 countries globally.

The US program consists of 17 regional programs whose panels of independent judges select the regional award winners every June. Those winners compete for national recognition at the Strategic Growth Forum® in November where National finalists and award winners are announced. The overall National winner represents the US at the EY World Entrepreneur Of The Year™ competition. Visit ey.com/us/eoy.

About EY
EY is building a better working world by creating new value for clients, people, society and the planet, while building trust in capital markets.
Enabled by data, AI and advanced technology, EY teams help clients shape the future with confidence and develop answers for the most pressing issues of today and tomorrow.

EY teams work across a full spectrum of services in assurance, consulting, tax, strategy and transactions. Fueled by sector insights, a globally connected, multi-disciplinary network and diverse ecosystem partners, EY teams can provide services in more than 150 countries and territories.

All in to shape the future with confidence.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Tucker Bedingfield
Galt Companies
+1 855-965-2783
email us here
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Galt Pharmaceuticals Expands Pain Management Portfolio

tolectinds logo

Galt Pharmaceuticals Expands Pain Management Portfolio with Tolectin DS® (Tolmetin Sodium 400mg Capsules)

Scott Chappell
Scott Chappell

Galt Pharmaceuticals Director of Medical Affairs

Galt Pharmaceuticals proudly announces the introduction of Tolectin DS® (Tolmetin Sodium 400mg Capsules), to it’s growing non-opioid pain product portfolio.

ATLANTA, GEORGIA, USA, May 9, 2024 /EINPresswire.com/ — Galt Pharmaceuticals, a pioneer in developing non-opioid pain management solutions, is proud to announce the introduction of Tolectin DS to its product portfolio. This launch underscores the company’s unwavering commitment to revitalizing safe, effective, non-controlled pain treatments that have been overshadowed by opioid therapies.

Barry Patel, Pharm.D., CEO and Co-Founder of Galt, expressed enthusiasm about the addition, stating, “We are delighted to enhance our portfolio with Tolectin DS, a product known for its distinct clinical benefits. It’s crucial to revisit and promote safe, proven options for pain management that have been neglected due to the widespread marketing of opioids. Our commitment remains strong in reintroducing trusted therapies to the market.”

“It’s crucial to revisit and promote safe, proven options for pain management that have been neglected due to the widespread marketing of opioids.”
— Barry Patel, Pharm.D., CEO and Co-Founder of Galt Pharmaceuticals

Tolectin DS is an FDA-approved Non-Steroidal Anti-Inflammatory Drug (NSAID) formulated to address pain associated with osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis. Suitable for both acute flare-ups and long-term management, Tolectin DS achieves peak plasma concentration within 30-60 minutes, offering prompt and reliable relief.

Adding to the discourse, Wade Smith, Pharm.D., Chairman and Co-Founder of Galt, noted, “Following the success of our musculoskeletal pain reliever Norgesic, Tolectin DS will further enrich our offerings by targeting bone and joint pain, thereby providing healthcare professionals with options to manage either muscle or bone pain effectively and safely.”

Galt will introduce Tolectin DS through its innovative pharma franchise model (Galt Phranchise Systems) and partnerships with Independent Community Pharmacies to enhance distribution and accessibility. Adam McCown, Pharm.D., owner of Medmetrics Pharmacy in Arizona and a Galt franchisee since 2018, remarked, “Our partnership with Galt has been instrumental in expanding our business. The addition of Tolectin DS will further accelerate our growth while enhancing our capability to meet the evolving needs of our customers.”

For more information about Tolectin DS or to schedule an interview, please contact Tucker Bedingfield at 855-965-2783

About Galt Pharmaceuticals
Based in Atlanta, GA, Galt Pharmaceuticals is a unique pharmaceutical company that develops and commercializes prescription medications that help satisfy the unmet clinical needs of many patient types. Galt leverages business intelligence to identify, develop and bring high-value pharmaceutical products to market through distinctive approaches which include partnerships with independent community pharmacies and entrepreneurs within its franchise network.www.galtrx.com

About Galt Phranchise Systems
Galt Phranchise™ Systems (GPS) is the first and only franchisor to partner with a pharmaceutical company that allows an entrepreneur or business entity to market and promote pharmaceutical and health-related products in local markets. www.galtps.com

About Tolectin DS (Tolmetin Sodium)
Tolmetin Sodium is an FDA-approved Non-Steroidal Anti-Inflammatory Drug (NSAID) indicated to treat pain associated with osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis. Tolmetin may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke which can be fatal. Tolmetin may also cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Healthcare professionals and patients should report any adverse events associated with Tolectin to the FDA’s MedWatch program at 1-800-FDA-1088 or www.fda.gov/medwatch.

Tolectin DS is a registered mark of Galt Pharmaceuticals.
Tucker Bedingfield
Galt Pharmaceuticals
+1 855-965-2783
email us here
Visit us on social media:
LinkedIn
YouTube

Galt Aims to Disrupt Status Quo with 4-Day Workweek

Galt Aims to Disrupt Status Quo with 4-Day Workweek

Scott Chappell
Scott Chappell

Galt Pharmaceuticals Director of Medical Affairs

Galt’s decision was based on lessons offered by the pandemic, along with research showing an increase in productivity and creativity brought about by the 4-day workweek model.

Galt Pharmaceuticals Co-founder and CEO Barry Patel/Courtesy of Galt Pharmaceuticals.

Galt Pharmaceuticals is just a little bit different. With a centralized business model aimed at disrupting the status quo of big pharma, the company recently implemented a 4-day, 36-hour workweek that tilts at a disruption happening across the North American workforce.

The Marietta, GA-based outfit, whose trademarks include products for pain, insomnia and oral thrush, takes its name and inspiration from the protagonist, John Galt, in the novel Atlas Shrugged by Ayn Rand. Galt is of the philosophy that an individual with a strong will and work ethic can break down manmade barriers and achieve anything he or she desires, and Galt Pharmaceuticals believes the same.

The company’s new flexible workplace policy is a testament to its employees’ drive and dedication, which shone through when the COVID-19 pandemic set in.

“Our business really continued without fail,” said Tracey Define, Galt’s vice president corporate systems. “It was a very easy decision to make because we really learned from the pandemic that our staff is committed, and if we do need them to go an extra mile, it’s never a question.”

The leadership came to the decision after reflecting on the lessons offered by the pandemic, along with research showing an increase in productivity and creativity brought about by the 4-day workweek model. Define summed up these takeaways.

“A shorter workweek allows people to really focus on creativity because it’s in the breaks when creativity happens,” she said. “It’s not when you’re toiling at your desk, focusing on numbers or e-mails. It’s when you have an actual break to just relax and let your mind be open.”

The three-day weekend is a central part of the strategy.

“There’s actual science behind why you feel more relaxed after three days. It takes that amount of time to really decompress and let go of the stress, so that you have the energy and excitement to get back at things on Monday,” Define explained.

Thinking outside of the box is the norm for Galt, which was founded with the mission of finding a better way to do things. Its business model is based on disrupting the inefficient models and bureaucracies of “big pharma” through a franchising model.

The company consists of local business owners it calls “Phranchisees” who run Phranchises™ in 55 territories across the U.S. committed to healthcare provider engagement and product representation. These entrepreneurs employ their own sales and marketing associates, further decentralizing the operation.

Co-founders Wade Smith and Barry Patel, both pharmacists with extensive knowledge of the pharmaceutical industry, were motivated to launch this model to fix the inefficiencies they experienced first-hand. Patel, who serves as Galt’s chief executive officer, explained how the benefits get passed down to the patient.

“The disruption piece is really allowing for the businesses in the pharmaceutical sector to be run in the way that they need to be, in the specific markets that they are in,” he said. “They can be much more efficient because they can react to the needs of their individual healthcare community.”

While in the typical big pharma model, patient assistance and access questions are channeled through a large corporate office, Patel explained that Galt’s model allows for more patient-centricity.

“We can address those down on the ground, because you’ve got owners that have good relationships with their local pharmacists and the prescribers,” he said.

This allows Galt to ensure the patient receives the best product at the lowest possible cost, even in the absence of insurance. In the same vein, the company places a priority on working with independent pharmacies.

“They are a lot more patient responsive than chain pharmacies and some of these other places that are driven to be more number oriented, so we’re able to get to the root of any issues that patients may be having about a product a lot quicker,” Patel said.

Territory owners and sales partners in each territory are also given flexibility in terms of time management. Define explained that this enables better patient support.

“They make decisions about where and how they spend their time, which allows for the creation of deeper relationships with the healthcare providers that they see and work with every day,” she said.

Patel stated that Galt’s product strategy follows this same patient-centric philosophy.

“As pharmacists, we have sort of nostalgia about products that worked in the past, but then ended up on the shelf or just taken off the market because [companies] didn’t want to continue the marketing fees and so forth. So we look at which markets are still not satisfied from an unmet need perspective,” he said.

This is how Galt decided on the insomnia space, which experiences a significant amount of churn, and the pain market where Patel said there is a concentration of opioid drugs. Galt’s Norgesic Forte® is a non-opioid, non-controlled medicine intended to help relieve acute musculoskeletal pain.

“There’s nothing else out there right now being marketed in that category, and opioids were over-marketed for years and years,” he said. “So, we’re bringing something older to the market, but with a fresh look.”

So far, Patel said that Galt’s latest foray into model disruption is eliminating even more inefficiencies.

“What I’ve seen in these few short weeks is that people are more efficient in how they get their work done during those four days, because they know there’s no time for idle meetings or things that might not make sense,” he shared.

In the current employment climate of “The Great Resignation”, Define advises any company with the capacity to try the 4-day week to give it a shot.

“Employee satisfaction really should be number one on every employer’s to-do list, because I know for our small company, we couldn’t afford to lose one person,” she said.

Galt Pharmaceuticals Acquires Oravig® (Miconazole Buccal Tablets 50mg) from Fortovia Therapeutics

Galt Pharmaceuticals Acquires Oravig® (Miconazole Buccal Tablets 50mg) from Fortovia Therapeutics

Scott Chappell
Scott Chappell

Galt Pharmaceuticals Director of Medical Affairs

ATLANTA–(BUSINESS WIRE)–Galt Pharmaceuticals announced the acquisition of a specialty branded product from Fortovia Therapeutics. Effective December 2, 2020, Galt added Oravig®, the first and only orally-dissolving buccal tablet for oral thrush, to its growing portfolio of pharmaceutical assets.

“We are thrilled to add a branded product with distinctive clinical benefits to our growing product portfolio,” stated Barry Patel, CEO and co-founder of Galt. “We are committed to offering unique products that support unmet clinical needs to improve patients’ quality of life.”

Oral thrush is an infection of the mouth caused by the Candida fungus, also known as yeast. The condition can affect people of all ages including older adults and those with weakened immune systems.

The deal represents a large market opportunity for the Atlanta-based pharmaceutical company. Of the approximately 28 million total prescriptions currently written, filled and dispensed for oral thrush annually in the U.S., more than 22 million are filled for oncology and primary care patients, according to IQVIA Health.

Wade Smith, PharmD, chair and co-founder of Galt added, “Oravig is a specialty product that fits nicely in our phranchise distribution model. It is the third product in our portfolio in as many years. We look forward to supplying Oravig to our phranchisees – just as we have Doral and Orphengesic Forte – both of which achieved record sales in 2020.”

Galt will launch Oravig in Q1 2021 through its unique phranchise sales and distribution model that leverages collaboration with independent pharmacies.

Visit www.Oravig.com for important safety information and full prescribing information.

About Galt Pharmaceuticals

Galt Pharmaceuticals has found a better way to enhance the quality of life of patients with products that answer unmet clinical needs, while creating life-changing opportunities for entrepreneurs, our employees and the individuals within the communities we serve.

Galt is the first and only company to create a unique pharmaceutical franchise or “Phranchise” concept that moves product representation away from corporate headquarters into local communities. Phranchises provide education to local healthcare providers while Galt manages functions such as drug research, regulatory approval, compliance and supply chain.

Learn more at www.GaltRX.com.

About Oravig

Oravig is the first and only muco-adhesive buccal tablet formulation of miconazole approved to treat oropharyngeal candidiasis (OPC), also known as oral thrush, in adult patients in the United States.

Do not use Oravig if there is a known or suspected hypersensitivity to any of its ingredients. Allergic reactions, including anaphylactic reactions and hypersensitivity, have been reported with the administration of miconazole products, including Oravig. Discontinue Oravig immediately at the first sign of hypersensitivity.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Important Safety Information and Full Prescribing Information for more details.

 

Contacts

Christy Rosell, 404.409.7759
christy@clearwingcommunications.com

 

Opioid-free Pain Med Orphengesic Forte by Galt Pharmaceuticals Approved by FDA

Opioid-free Pain Med Orphengesic Forte by Galt Pharmaceuticals Approved by FDA

Scott Chappell
Scott Chappell

Galt Pharmaceuticals Director of Medical Affairs

ATLANTA–(BUSINESS WIRE)–Pharmaceutical innovator Galt Pharmaceuticals announced a new drug approval to offer a non-opioid, non-controlled, non-addictive alternative for healthcare providers to manage patients suffering from pain. On July 8, 2020 the U.S. Food and Drug Administration approved the company’s Supplemental Abbreviated New Drug Application for Orphengesic Forte, over two months ahead of the scheduled goal date.

“This is a big win in the fight against the U.S. opioid epidemic and the FDA’s swift early action confirms the seriousness of the issue,” said CEO and co-founder Barry Patel, Pharm.D. “Orphengesic Forte is a proven safer pain management alternative healthcare providers can consider before prescribing an opioid.”

Orphengesic Forte is indicated for the relief of mild to moderate pain of acute musculoskeletal disorders, paired with rest, physical therapy and other measures.

“The medical community is in great need of alternative therapeutic options to treat pain and Orphengesic Forte helps to meet that need because pain is very personal,” said Tapan Daftari, M.D., an orthopedic surgeon with Resurgens Orthopedics.

The Centers for Disease Control & Prevention reports 20% of U.S. adults are affected by chronic pain – one of the most common reasons adults seek medical care.

“Management of pain in the United States is a significant issue impacting quality of life for millions of adults,” said Galt Chairman and Co-Founder Wade Smith, Pharm.D. “Patients deserve more options from the best health care system in the world and that’s why we’re committed to expanding our portfolio with more pain medications in coming years.”

About Galt Pharmaceuticals

Galt Pharmaceuticals has found a better way to enhance the quality of life of patients with products that answer unmet clinical needs, while creating life-changing opportunities for entrepreneurs, our employees and the individuals within the communities we serve.

Galt is the first and only pharmaceutical company to create a unique pharmaceutical franchise or “Phranchise” concept that moves product representation away from corporate headquarters into local communities. Phranchises provide education to local healthcare providers while Galt manages functions such as drug research, regulatory approval, compliance and supply chain.

Learn more at www.GaltRX.com.

About Orphengesic Forte

INDICATIONS AND USAGE

Orphengesic Forte (Orphenadrine Citrate, Aspirin and Caffeine 50 mg/ 770 mg/60 mg) Tablets are indicated in:

1. Symptomatic relief of mild to moderate pain of acute musculoskeletal disorders.

2. The orphenadrine component is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.

The mode of action of orphenadrine has not been clearly identified, but may be related to its analgesic properties. Orphengesic Forte Tablets do not directly relax tense muscles in man.

IMPORTANT SAFETY INFORMATION (ISI)

Contraindications

Orphengesic Forte is contraindicated in patients with glaucoma, pyloric or duodenal obstruction, achalasia, prostatic hypertrophy, obstructions at the bladder neck, myasthenia gravis, hypersensitivity to the drug, and known sensitivities to aspirin or caffeine.

Warnings and Precautions

  • Orphengesic Forte is not recommended in patients with chicken pox, influenza, or flu symptoms due to the possible development of Reye’s Syndrome. Reye’s Syndrome is possibly associated with the use of aspirin.
  • Patients should be cautioned on possible impairment of the ability to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle.
  • Aspirin should be used with extreme caution in the presence of peptic ulcers and coagulation.
  • Safety of use of Orphengesic Forte in pregnancy, during lactation, or in the child-bearing age has not been established; the potential benefits should be weighed against the possible hazard to mother and child.
  • The safe and effective use in children has not been established; Usage in children under 12 is not recommended.
  • Confusion, anxiety, and tremors have been reported with concomitant propoxyphene and orphenadrine.
  • Safety of continuous long term therapy with Orphengesic Forte has not been established; If prescribed for prolonged use, periodic monitoring of blood, urine, and liver function values is recommended.

Adverse Reactions

The side effects of Orphengesic Forte are those seen with aspirin and caffeine or those usually associated with mild anti-cholinergic agents. These may include tachycardia, palpitation, urinary hesitancy or retention, dry mouth, blurred vision, dilation of the pupil, increased intraocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, and drowsiness.

For more safety information and the complete list of adverse reactions, please see the Full Prescribing Information for Orphengesic Forte.

Contacts

Christy Rosell, 404.409.7759
christy@clearwingcommunications.com